Luboldt H J, Kubens B S, Rübben H, Grosse-Wilde H
Department of Urology, Medical School Essen, Germany.
Cancer Res. 1996 Feb 15;56(4):826-30.
The expression of human leukocyte antigen (HLA) class I alleles was analyzed in 65 renal cell carcinomas using one-dimensional isoelectric focusing. Normal organ tissue and peripheral blood lymphocytes were used as controls. The patients were serologically typed using the standard microcytotoxicity test. Forty-two patients were staged as pT1 or pT2, and 23 patients had advanced tumor stages (pT3/pT4). In all cases the HLA-A,B phenotypes were confirmed using one-dimensional isoelectric focusing. The expression of HLA expression was reduced in two tumors [1 x HLA-A1(pT2); 1 x HLA-A28 (pT2)]. In three carcinomas the expression of HLA-A1 was lost. One tumor showed a combined loss of HLA-A2 and HLA-B38. These selective losses occurred in tumor stage pT3 (n = 1) or pT4 (n = 3; P = 0.013, Fisher's exact test). This leads to the conclusion that the loss of HLA expression is predominantly present in advanced tumor stages.
采用一维等电聚焦法分析了65例肾细胞癌中人类白细胞抗原(HLA)I类等位基因的表达情况。以正常器官组织和外周血淋巴细胞作为对照。采用标准微量细胞毒性试验对患者进行血清学分型。42例患者分期为pT1或pT2,23例患者为晚期肿瘤分期(pT3/pT4)。在所有病例中,均采用一维等电聚焦法确认HLA-A、B表型。在2个肿瘤中HLA表达降低[1例为HLA-A1(pT2);1例为HLA-A28(pT2)]。在3例癌中HLA-A1表达缺失。1个肿瘤显示HLA-A2和HLA-B38联合缺失。这些选择性缺失发生在肿瘤分期pT3(n = 1)或pT4(n = 3;P = 0.013,Fisher精确检验)。由此得出结论,HLA表达缺失主要出现在晚期肿瘤分期。